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Purpose: This study used ultrasonography (US) to investigate the architectural 
changes in gastrocnemius muscles (GCM) after botulinum toxin injection (BoNT-
A) in children with cerebral palsy (CP). Materials and Methods: Thirteen chil-
dren with CP who received a BoNT-A injection into their GCM to treat equinus 
were recruited (9 males and 4 females). Architectural changes in both the medial 
and lateral heads of the GCM from a total of 20 legs were assessed using B-mode, 
real-time US. Muscle thickness (MT), fascicle length (FL), and fascicle angle (FA) 
were measured over the middle of the muscle belly in both a resting and neutral 
ankle position. Measures at 1 and 3 months after the injection were compared with 
baseline data taken before the injection. Results: The mean age of the subjects was 
5.8 (±1.6) years. Spasticity was significantly reduced when measured by both the 
modified Tardieu scale and the modified Ashworth scale at 1 and 3 months after 
injection (p<0.05). The MT and FA of both the medial and lateral heads of the 
GCM were significantly reduced for both neutral and resting ankle positions at 1 
and 3 months after the injection. The FL of both the medial and lateral heads of the 
GCM were significantly increased in a resting position (p<0.05), but not in a neu-
tral position. Conclusion: Our results demonstrated muscle architectural changes 
induced by BoNT-A injection. The functional significances of these changes were 
discussed.
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INTRODUCTION
Cerebral palsy (CP) is a group of permanent motor disorders that are attributed to 
a non-progressive lesion in immature brains. Spasticity is the most common type 
of CP, and can involve disabling features that lead to limited motor learning and 
locomotor abilities, which can then contribute to development of joint contractures 
and deformities causing further functional impairments. As well, spasticity can 
also lead to significant structural alterations in muscles.1 Therefore, many thera-
peutic interventions, including physical modalities, anti-spastic drugs and orthoses, 
have been employed in an attempt to reduce spasticity.2 Injection of botulinum 
toxin type A (BoNT-A) into spastic muscles is widely used as a safe and effective 
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muscles (GCM). Distributions of Gross Motor Function 
Classification System were widely distributed from level I 
to IV (level I, 6; level II, 4; level III, 1; level IV, 2). 
Ethical approval was granted by the Institutional Review 
Board and Ethics Committee of Severance Hospital (#4- 
2007-0066). Informed consent was obtained from parents 
of the children for participation in the study.
Clinical measures of spasticity 
Muscle tone of the ankle plantar flexor in knee extension 
was assessed with the modified Ashworth scale (MAS) and 
modified Tardieu scale (MTS). MAS is a 6-point rating scale 
from 0 to 4 used to gauge muscle tone. For statistical analy-
sis, MAS grade 1(+) was converted to 2. Likewise, MAS 
grades 2, 3, and 4 were converted to 3, 4, and 5, respectively. 
As for MTS, two levels of passive range of motion (ROM) 
were measured, referring to R1 and R2 angles: R2 refers to 
the total passive ROM of ankle dorsiflexion, while R1 re-
fers to the point in the ROM where a catch was felt during 
a quick stretch of the ankle plantarflexor. The ankle joint 
angles for R1 and R2 were measured by manual goniome-
try with the “neutral-null” method (dorsiflexion angle over 
the neutral position was counted in positive degrees, and 
the neutral in negative degrees13).
All measurements were taken before injection and at 3 
months after injection. 
Interventions
BoNT-A was delivered equally to both the medial and lateral 
heads of the GCM. The injections were performed under the 
guidance of US with the child in the prone position. The total 
units of the toxin per child were determined depending on 
the severity of spasticity and body weight. Overall, 4 units 
per kilogram of Botox® (Allergan, Inc., Irvine, CA, USA) or 
13 units per kilogram of Dyport® (Ipsen Biopharmaceuticals, 
Inc., Basking Ridge, NJ, USA) were delivered for each GCM. 
There were no serious adverse effects of the toxin injections. 
All children underwent physical therapy twice per week, but 
no additional strengthening program or intensive treatment 
was given to the subjects. Also, the subjects were given an 
ankle foot orthosis (AFO), and wearing of AFOs was en-
couraged during the day time as long as possible.
None of the subjects had additional serial or short leg 
casting after injection. 
Ultrasound measures
For US, subjects were positioned prone on the examination 
intervention for pediatric spastic management. Dynamic 
equinus deformity is frequently targeted for BoNT-A injec-
tion, and significant beneficial effects of the injection have 
been repetitively reported in the literature on both spasticity 
reduction and functional improvement. 
Notwithstanding, previous studies have revealed that tox-
in injection into non-spastic muscles induces muscle atro-
phy in both animal3-6 and human models.7 A previous report 
demonstrated muscle atrophy and loss of contractile tissue 
with repetitive toxin injection into non-spastic muscles of 
rabbits.8 There is a widespread concern that BoNT-A injec-
tions may compromise muscle growth in volume and exacer-
bate loss of underlying muscle strength, especially in young 
children with spastic CP. However, the impact of the toxin 
on spastic muscle function has been sparsely reported, es-
pecially in children with CP. 
Musculoskeletal ultrasonography (US) is considered a 
potential tool for quantifying muscle architectural changes 
in vivo, revealing the arrangement of muscle fibers within a 
muscle.9 With the use of musculoskeletal US, morphologi-
cal changes in the architecture of paretic muscles has re-
cently been reported in children with spastic CP in compar-
ison to both the muscles of non paretic limbs of children 
with CP and typically developing children.10 To the best of 
our knowledge, architectural changes in spastic muscles af-
ter BoNT-A injection have not yet been reported in children 
with CP. Therefore, the purpose of our study was to investi-
gate the effect of BoNT-A injections on muscle architecture 




Among children with spastic CP who visited our clinic for 
therapeutic intervention from March 2011 to April 2012, 
the children who met the following criteria were recruited 
for this study: 1) presence of dynamic equinus foot due to 
ankle spasticity, 2) without previous history of chemode-
nervation, serial casting, or surgery within 6 months, and 3) 
children whose parents agreed to BoNT-A injection for dy-
namic foot deformity. 
In total, 13 children (9 males and 4 females) with ages 
ranging from 4 to 8 years (69.7±18.6 months; mean±SD) 
were enrolled in this study. Six limbs from 6 children with 
hemiplegic CP and 14 limbs from 7 children with diplegic 
CP underwent BoNT-A injection into their gastrocnemius 
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Statistical analysis was conducted using IBM SPSS statis-
tics version 16.0.0 (IBM, New York, NY, USA). For statis-
tical analysis, a Wilcoxon signed-rank test was used to as-
sess differences between baseline data and the data after 




Spasticity was significantly reduced after BoNT-A injec-
tion. Both R1 and R2 measured by MTS were significantly 
increased, while the measurements in the MAS were signif-
icantly decreased, compared with baseline data (Fig. 2). 
The FL of the medial and lateral heads of the GCMs was 
significantly increased at 1 and 3 months after injection, 
compared with the baseline data measured in the resting an-
kle position (p<0.05). These changes were not observed in 
the neutral position.   
Both the FA and MT of the medial and lateral heads of the 
GCMs in both the resting and neutral ankle positions at both 1 
and 3 months after the injection were significantly decreased 
when compared with baseline data (p<0.05) (Table 1).
DISCUSSION
Significant reduction in muscle volume of paretic limbs in 
individuals with cerebral palsy as demonstrated by magnet-
bench with their feet hanging over the edge of the bench. 
Tibia length (TL) was measured from the most prominent 
point of the lateral malleolus to the fibular head. Points at 
the top 25% and 30% of TL were marked with a fiber-tip 
pen. US images at both of these marked points of the TL 
were taken for measuring muscle thickness in a resting po-
sition and a neutral ankle position in order to avoid possible 
changes due to measurement location.
Neural ankle angle was defined as 90° between the line 
of the fibula and the base of the lateral foot. The neutral an-
kle position while taking the images was maintained by an 
assistant. 
US images of GCMs were taken by one trained physician 
using B-mode and real-time ultrasonography (Accuvix V10c 
system; Samsung Medison Co., Discusser & Medison Build-
ing, 1003 Daechi-dong, Gangnam-gu, Seoul, South Korea) 
with a scanning frequency from 5 to 12 megahertz. The US 
image was obtained following the recommendations of Bé-
nard, et al.14 in order to minimize measurement error.
Muscle thickness (MT) is a measurement of the longest 
distance between the fascia of the GCMs in a cross section-
al US image. Muscle fascicle length (FL) was defined as 
the straight-line distance between the upper muscular fascia 
and the lower muscular fascia parallel to the lines of the 
collagenous tissue visible on the image. This measurement 
was consistently made in the middle of the image where the 
full length of the fascicle could be visualized. The fascicle 
angle (FA) was defined as the angle made between the up-
per fascia (i.e., the line of action of the tendon) and the di-
rection of the muscle fascicles (Fig. 1).15
All measurements were taken before injection and at 3 
Fig. 1. Ultrasonographic measurements of muscle thickness (A), fascicle length (B), and fascicle angle (C). (A) Muscle thickness: the longest distance be-
tween fascia of gastrocnemius muscle in cross sectional ultrasound image. (B) Fascicle length: the length of muscle fiber between fascia in longitudinal ul-
trasound image. (C) Fascicle angle: the angle between muscle fiber and estimated parallel fascia line in longitudinal ultrasound image.  
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veloping children,18 and also correlated with the functional 
level of children with CP.19 These findings suggest that the 
muscle thickness measured with US in children with CP 
can be used as an alternative measure to quantitatively eval-
uate muscle strength.19 Our study revealed a significant re-
duction in MT measured both at 25% and 30% of the TL 
after toxin injection. 
The locations for the MT and volume measurements us-
ing US differ in the literature, with some groups reporting 
measurement at two-thirds of the muscle belly length,14 oth-
ers measuring at the mid portion of the muscle belly,20 and 
some measuring at the most bulky part of the muscle bel-
ly.11 According to a previous study, there is no significant 
ic resonance imaging (MRI) in comparison with both non-
paretic limbs and in typically developing peers has been re-
ported in the literature.7,16 In vivo US imaging has been 
successfully applied in studies of muscular geometric archi-
tecture in the human body. Compared to MRI, US imaging 
is less expensive and more convenient and has thus gained 
popularity as a tool to assess the parameters of muscle geo-
metric architecture in vivo.
According to a previous report, MT measured using US 
is highly correlated with the cross sectional area measured 
using MRI in children with spastic cerebral palsy.17 More-
over, MT measured by US was highly correlated with vol-
untary muscle torque in children with CP and typically-de-
Fig. 2. Changes of spasticity after botulinum toxin type A injection. (A) Changes of modified Ashworth scale after botulinum toxin type A injection. (B) 
Changes of modified Tardieu scale after botulinum toxin type A injection. *Before injection-injection after 1 month are significantly different. †Before injec-
tion-injection after 3 months are significantly different: p value <0.05 in Wilcoxon signed rank test. R1, the point in the ROM where a catch was felt during a 










































Table 1. Architectural Changes after Botulinum Toxin Type A Injection 
Medial head Lateral head
Resting Neutral Resting Neutral
Fascicle length (mm)
    Before   2.96±0.98   3.98±1.51   2.91±0.80   3.35±1.16
    After 1 month   3.28±0.94*   4.00±1.25   3.18±0.88*   3.45±1.02
    After 3 months   3.35±1.04†   4.02±1.41   3.29±1.11   3.55±1.13
Fascicle angle (°)
    Before 23.08±5.62 18.20±5.07 17.71±5.19 12.59±4.70
    After 1 month 20.40±4.43* 16.86±3.66 13.56±2.92* 10.91±2.77
    After 3 months 18.62±5.11† 15.41±3.54† 12.67±4.13†   9.19±2.48†
Muscle thickness at 25% of tibial length (mm)
   Before   1.11±0.28   1.19±0.34   0.83±0.25   0.84±0.23
    After 1 month   1.04±0.25*   1.10±0.32*   0.72±0.17*   0.71±0.24*
    After 3 months   0.99±0.29†   1.06±0.33†   0.65±0.20†   0.65±0.19†
Muscle thickness 30% of tibial length (mm)
    Before   1.01±0.28   1.11±0.33   0.69±0.24   0.75±0.22
    After 1 month   0.93±0.26*   1.00±0.30*   0.58±0.23*   0.61±0.26*
    After 3 months   0.88±0.31†   0.96±0.31†   0.52±0.25†   0.53±0.22†
*Before injection-injection after 1 month are significantly different.
†Before injection-injection after 3 months are significantly different: p value <0.05 in Wilcoxon signed rank test. 
* †
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muscles in children and adolescents with CP, compared with 
age matched typically developing participants.9
Our study revealed a significant decrease in FA in both 
resting and neutral positions, whereas FL was only increased 
in the resting position after the toxin injection. This similar 
change was also demonstrated in the hemiplegic side of 
stroke patients 2 months after injection when the US exam-
ination was performed in the resting ankle position with 
knee extension.11 According to previous studies, the FL and 
FA of GCM changed systematically with knee and ankle po-
sition.26,28 However, the ankle and knee positions, along with 
the subject’s position during the US imaging, were not the 
same across studies.11,12,14 These sampling issues may be a 
reason for the discrepancy of the results from previous stud-
ies in regards to FL. From this perspective, the FL changes 
after injection in our study in the resting position would dif-
fer from the neutral position. Resting positions of the ankle 
joint may differ according to spasticity of calf muscles in 
children with spastic CP. However, no differences in FL for 
ankles in a neutral position indicated that there were no sig-
nificant differences in FL in the same ankle position. These 
findings are in accordance with Shortland, et al.’s report. 
However, studies of FL in children with CP are still grow-
ing. Standardization of methodology in regards to a sub-
ject’s position and ankle and knee positions for examination 
of muscle architectural changes is needed to compare re-
sults across the literature and also to delineate their clinical 
implications. 
FL is proportional to the maximum excursion of the mus-
cle and velocity of contraction, and is indicative of the num-
ber of sarcomeres in series, whereas the FA is the positive 
angle between muscle fibers and the aponeurosis of the 
muscle.9 An increase in FA indicates an increase in the mus-
cle’s capacity to produce force.9,29 Previous reports demon-
strated a significant relationship between MT and FA,29 as 
well as a significant decrease in FA in response to disuse.30-32 
Both muscle atrophy and decrease in FA of vastus lateralis 
muscles may be contributing factors to the decreased force 
production of the quadriceps observed in CP.9 Therefore, 
the decreases in FA and MT after injection in our study sug-
gest a negative influence of the toxin on muscle force pro-
duction. However, there is still very limited data on morpho-
logical and structural alterations in individuals with spastic 
CP after intervention for spasticity. Furthermore, the func-
tional significance of these parameters requires further in-
vestigation in these children, along with resolution of dif-
ferences in sampling issues. 
difference in measurement of the MT between the three 
measurement locations (proximal, central, and distal medial 
GCM).21 We also discovered a similar pattern in the MT 
changes between two of the measurement locations. 
A significant reduction in MT was also previously demon-
strated at 2 months after toxin injection in hemiplegic stroke 
patients; MT was measured at 10 days and at 2 months after 
injection.11 These findings are in accordance with our find-
ings. Since the high correlation of MT with muscle volume 
or torque was found in previous literature,18 the reduction in 
muscle thickness after injection suggests negative influenc-
es of the toxin on muscle strength and growth. On the con-
trary, Williams, et al.22 found that muscle strength and vol-
ume in children with CP were increased, compared with 
baseline data, after BoNT-A injection with natural growth 
and standard care.
However, the subjects in that study received standard care 
programs before and after injection for up to 24 weeks. The 
increases in strength and muscle volume were greater with 
addition of a strengthening program with BoNT-A injec-
tion.22 On the other hand, the children of our study received 
only routine physical therapy. Accordingly, these differenc-
es in the intensity and frequency of physical treatment ad-
ministered to the subjects may account for the discrepancy 
in the changes of muscle size between these two studies. 
Nevertheless, the intensity of physical therapy and strength-
ening needed to overcome the negative influence on muscle 
size induced by the toxin injection remains to be studied. In 
many previous studies, the importance of intensive physical 
therapy after the injection was emphasized for enhancing 
the functional outcome of children with CP.22,23 On the other 
hand, there is consistent evidence for significant muscle vol-
ume reduction in paretic limbs of spastic CP, compared with 
both non paretic and normally developing children.1,20,24,25 
Taken together, our results also support the notion of the 
importance of intensive physical therapy and strengthening 
programs in regards to muscle size.
Notwithstanding, the evidence is inconsistent for reduc-
tion of FL. Some reports revealed no differences in FL be-
tween children with CP and typically-developing children 
and between paretic and non-paretic limbs,1,12,20,25,26 whereas 
others demonstrated a significant reduction in FL in spastic 
muscle.9,10 However, there are only a few reports about FL 
in children with CP. Shortland, et al.’s27 report demonstrated 
that there were no significant differences in FL between chil-
dren with diplegic CP and typically developing children. An-
other report demonstrated smaller FL of vastus lateralis 
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timing of disappearance of the toxin effect on muscular ar-
chitecture with long-term follow-up, and changes to repeti-
tions of toxin injection have to be investigated further in or-
der to delineate the strengths and weakness of the toxin on 
muscle function in children with CP.
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